A Agilent Technologies Inc.

Agilent Independent Global Lab Sustainability Survey Sheds Light on Progress Towards Greener Labs

(NYSE: A) today announced the results of an independent third-party global survey that will help the industry better understand analytical laboratories’ perceptions, aspirations, and challenges concerning implementing sustainability measures.

Conducted on behalf of Agilent by the international market research firm , the survey sought to understand how lab managers globally are thinking about sustainability and reducing the environmental impact of their labs and how vendors like Agilent can help by improving products and services to address their needs and current gaps.

The survey took a two-phased approach with 100 qualitative phone interviews, followed by 500 online interviews with experienced lab personnel in Asia, Europe, the United Kingdom, and the United States across all the lab types and market segments Agilent serves. The primary functions of the labs surveyed were analytical services, methods development or validation, process control, monitoring or manufacturing, quality assurance or control, research, and clinical testing.

The results indicated that a high percentage (82%) of labs surveyed have already adopted sustainability measures. The top three actions that labs are currently undertaking to reduce their environmental footprint are: reducing carbon and other greenhouse gas emissions (72%), reducing or optimizing water and energy consumption (68%), and improving waste management techniques (60%). Also, 85% of those surveyed expect their vendors to support them in reaching their sustainability goals, now and in the future, and 74% of labs stated that it would be an exclusion criterion for them to engage with a company commercially that did not have a .

“A majority of labs stated that information shared by vendors, related to their own goals and objectives towards sustainability, in addition to instrument and product-related information, was important,” said Neil Rees, head of Agilent’s ESG Programs. “Our ongoing partnership with and their program ensures that we can offer our customers third-party verified information on the environmental impact of Agilent solutions.”

“By providing the necessary verification and transparency of sustainability information, MGL ACT labels help consumers make informed decisions across the lifecycle impact of laboratory products,” said James Connelly, My Green Lab CEO. “Participating in ACT is a key way manufacturers demonstrate their commitment to our mission to build a global culture of sustainability in science.”

Additionally, 54% of labs would be interested in consulting services to assess and improve lab efficiency, followed by instruments and systems that support tracking and monitoring key metrics related to sustainability (44%). Labs are also looking to vendors to provide instrument end-of-life solutions, for example, recycling services (77%) and instrument refurbishment initiatives (51%), such as Agilent’s . Agilent also showcased a selection of its products at the held June 4 - 8 in Houston, Texas.

“As our customers’ definition of sustainability expands, it’s incumbent on us to be ahead of the curve in understanding their needs,” Rees added. “Independent surveys such as this provide clear and impartial feedback, identifying trends and gaps that we can action, to continue to provide solutions that help ensure our customers’ sustainability goals are met or exceeded.”

“It’s important that we share these results with the wider community as we are all on the journey to be more sustainable,” said Victoria Wadsworth, associate vice president of Reputation Marketing at Agilent. “By sharing these learnings, we can spark richer conversations and share best practices that bring everyone closer to their goals. It’s the right thing to do for business and our planet.”

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at . To receive the latest Agilent news, please subscribe to the Agilent . Follow Agilent on and .

EN
08/06/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approva...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics’ , a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise and reliable cell analysis solutions, Agilent assisted Autolus in achieving the high standards required for FDA approval. Dr. Xiaobo Wang, Vice President and General Manager of the Cell Functio...

 PRESS RELEASE

CORRECTING and REPLACING Agilent to Showcase Next-Generation Digital P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph. The updated release reads: AGILENT TO SHOWCASE NEXT-GENERATION DIGITAL PATHOLOGY SOLUTIONS AT USCAP 2025 (NYSE: A) is excited to announce its participation at the upcoming , which will be held March 22-27, 2025, in Boston. At the conference, Agilent will highlight innovative digital pathology solutions designed to enhance diagnostic accuracy and efficiency. In pathology, Agilent offers comprehensive tissue diagnostic solutions for analyzi...

 PRESS RELEASE

Agilent Research Catalyst Award Presented to Columbia University for P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced that has received an Agilent Research Catalyst (ARC) Award on behalf of , an internationally recognized researcher and physician-scientist specializing in bone marrow transplant (BMT) and cancer cellular immunotherapy. Dr. Muranski is the Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center. He is also an Assistant Professor of Medicine at Columbia University Medical Center, a principal investigator at the Columbia Center for Translational Immunology (CCTI), and a member of the Herbert Irv...

 PRESS RELEASE

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Com...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced its kit has received two new companion diagnostic indications approvals under EU IVDR1, expanding the eligibility of treatment to early-stage non-small cell lung cancer (NSCLC) and previously untreated advanced melanoma patients. These two new indications bring the total indications launched in Europe for PD-L1 IHC 28-8 pharmDx to nine. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the advanced staining solution. Lung cancer and malignant melanoma are major healthcare concerns worldwide, with lung cancer accountin...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch